Go Pro
NASDAQ:PSTV

Plus Therapeutics Q1 2026 Earnings Report

Plus Therapeutics logo
$1.78 -0.09 (-4.81%)
As of 10/1/2026

Plus Therapeutics EPS Results

Actual EPS
-$1.05
Consensus EPS
-$0.85
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A

Plus Therapeutics Revenue Results

Actual Revenue
$1.03 million
Expected Revenue
$0.97 million
Beat/Miss
Beat by +$54.00 thousand
YoY Revenue Growth
N/A

Plus Therapeutics Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Friday, May 15, 2026
Conference Call Time
4:00PM ET

Plus Therapeutics Earnings Headlines

Plus Therapeutics’ CNSide Begins Billing as Test Volumes Surge
The end of AI data centers coming?
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percent run, and Nvidia before it climbed more than 50,000 percent. Now Chaikin says a new AI data center technology using 99 percent less electricity, water, and space could accelerate scientific breakthroughs 360-fold, and one company behind it just flashed bullish in his system. See the full research and the ticker Chaikin is watching before this presentation goes offline.tc pixel
See More Plus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email.

About Plus Therapeutics

Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive agents directly to tumors while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposome, also known as 186RNL or RNL. The treatment uses nanoliposomes to encapsulate the radioisotope rhenium-186 and is being evaluated for cancers affecting the central nervous system, including recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics is also studying potential applications in other solid tumors.

Plus Therapeutics is headquartered in Austin, Texas, and conducts its development activities through collaborations with clinical and research institutions. The company was formerly known as Cytori Therapeutics before adopting the Plus Therapeutics name. Marc H. Hedrick serves as president and chief executive officer.

View Plus Therapeutics Profile